Articles, Explainers, Milestones
| 9 min read
Why you should test-drive your bioprocess in a pilot lab before committing to commercial scale.
| 9 min read
Welcome to the factory of the future, where automation runs the floor and digital twins run the decisions.
| 10 min read
You wouldn’t run a marathon on junk food; your continuous cell lines need a highly specialized diet.
| 10 min read
The CDMO selection is the headline. The tech transfer and quality agreement are where deals actually succeed or fail.
| 10 min read
Most biopharmaceutical programs will manufacture with a CDMO at some point. The programs that get it right plan for that partnership from the start.
| 8 min read
To pour concrete or to partner up? Here is the financial and strategic framework for navigating the build vs. buy decision in biomanufacturing.
| 8 min read
You've successfully manufactured the drug substance. Now, good luck finding a place to put it in a vial.
| 8 min read
The choice between AAV and lentiviral vector platforms is a manufacturing decision that determines everything downstream. Here is how to evaluate it.
| 8 min read
ADCs combine biological precision with chemical potency. Manufacturing them at scale requires mastering both.
| 8 min read
Bispecific antibodies require a precision engineering approach that conventional Protein A purification wasn't designed to handle.
| 9 min read
Making mRNA is the easy part. Getting it into cells safely and effectively is where formulation science makes or breaks the drug.
| 5 min read
How closed-system automation cuts contamination risk, cleanroom cost, and labor in autologous cell therapy manufacturing.
